What is the primary action of Betaxolol (Betoptic) in glaucoma management?

Betaxolol, marketed as Betoptic, primarily functions by suppressing aqueous inflow, making it effective in the management of glaucoma. This beta-blocker reduces the production of aqueous humor in the eye, which in turn lowers intraocular pressure. By minimizing the amount of fluid produced, it helps to prevent damage to the optic nerve often associated with elevated pressure in glaucoma.

Other options suggest mechanisms that do not align with the pharmacological action of Betaxolol. For instance, increasing aqueous humor production would contradict the drug's purpose in glaucoma treatment, as heightened production would elevate intraocular pressure. Similarly, decreasing aqueous outflow or enhancing drainage pathways do not accurately describe how Betaxolol operates; rather, these mechanisms may involve other classes of glaucoma medications. Understanding this specific action of Betaxolol helps frame it within the broader context of glaucoma therapy options.